prickle planar cell polarity protein 1Genealiases: EPM1B · RILP
Q-omics provides the consensus-scored PRICKLE1 profile across patient tissues and cancer cell-line models. PRICKLE1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PRICKLE1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PRICKLE1 RNA expression shows 17,896 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where PRICKLE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRICKLE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRICKLE1 survival associations across molecular data types. PRICKLE1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRICKLE1 RNA expression–survival associations across cancer types. High PRICKLE1 expression shows unfavorable associations in MESO and BLCA, but favorable associations in KIRP, ESCA, THCA and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PRICKLE1 RNA expression.
This table summarizes PRICKLE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PRICKLE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRICKLE1 shows lower tumor expression in KIRC, LUAD, COAD and KICH and higher tumor expression in THCA and BRCA. The KIRC box plot shows higher PRICKLE1 RNA expression in normal versus tumor tissue (log2 FC = −0.829, t-test p < 0.001).
This table shows molecular features associated with PRICKLE1 in patient tissues and cancer cell lines. In patient samples, PRICKLE1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRICKLE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
